Mopral (Omeprazole)

Omeprazole blocks the H+/K+ ATPase enzyme, also known as the gastric proton pump, on the surface of parietal cells. By irreversibly inhibiting this pump, it suppresses the final step of gastric acid secretion, leading to a sustained increase in gastric pH and reduced acidity.

The appropriate dose of Mopral is determined by the prescribing healthcare professional based on the specific indication, patient age, renal function, and treatment duration. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

Safety data for omeprazole in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their healthcare provider.

To order Mopral, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Mopral (omeprazole) belongs to the proton pump inhibitor (PPI) class, which generally provides more potent and longer‑lasting acid suppression than H2‑receptor antagonists such as ranitidine. Compared with newer PPIs like esomeprazole, omeprazole has a similar efficacy profile but may differ slightly in pharmacokinetics and cost.

Mopral should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain stability and potency throughout its shelf life.

Mopral is taken orally, usually as a whole tablet swallowed with a glass of water. It is generally recommended to take the dose before a meal, but patients should follow the specific instructions provided by their prescriber.

Serious adverse events, although rare, include severe allergic reactions (anaphylaxis), Clostridioides difficile‑associated colitis, and significant electrolyte disturbances such as hypomagnesemia. Long‑term use may also be linked to an increased risk of bone fractures and vitamin B12 deficiency.

Mopral is contraindicated in individuals with known hypersensitivity to omeprazole or any component of the formulation. Caution is advised for patients with severe hepatic impairment, and it should be avoided in those requiring concurrent clopidogrel therapy unless directed by a physician.